INTRODUCTION
Interstitial lung disease (ILD) is one of the most serious complications associated with connective tissue disease (CTD), resulting in significant morbidity and mortality. Rheumatologic diseases frequently complicated by ILD include systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), rheumatoid arthritis (RA), systemic lupus erythematous (SLE), Sjögren's syndrome, mixed connective tissue disease (MCTD), and undifferentiated connective tissue disease (UCTD). ILD may also be the first manifestation of CTD; up to 15% of patients initially diagnosed with idiopathic nonspecific interstitial pneumonia (NSIP) have underlying CTD on further investigation [1] . Prevalence, histologic/radiographic classification, and clinical manifestations vary between these conditions (Table 1) [2 & ].
There are many subtypes of ILD, originally defined histologically. Common types include usual interstitial pneumonia (UIP), NSIP, lymphocytic interstitial pneumonia (LIP), and organizing pneumonia (OP) (Fig. 1) . The most prevalent CTD-associated ILD is NSIP, followed by UIP. The UIP pattern is most commonly seen in RA, and typically portends a poorer prognosis, though still perhaps better than that of patients with idiopathic interstitial pneumonia (IIP) [3 The pattern and distribution of radiographic abnormalities observed on high-resolution computed tomography (HRCT) can accurately predict pathologic findings [7] , and scoring systems for HRCT have been shown to amplify prognostic yield in some conditions, especially SSc [8 && ,9 && ]. Many CTDs are also associated with noninterstitial pulmonary manifestations, which are outside the scope of this review.
Survival in patients with CTD-ILD is higher than in patients with IIP [10, 11] , attributed primarily to the higher prevalence of the favorable NSIP pattern [12, 13] . Most disease-specific prognostic data available are from SSc-ILD, in which median survival has been reported as 5-8 years [14 & ]. In these patients, the presence of UIP, severity of restriction on PFT, and extent of fibrosis on HRCT seem to be important prognostic variables [8 && ,9 && ]. Few studies exist in other CTD, though there is evidence suggesting that patients with RA-ILD have higher mortality rates than those with SSc-ILD, potentially because of the association between RA-ILD and UIP and the lack of routine screening for ILD in this population.
Management of CTD-ILD is challenging given the lack of robust data regarding the therapies used, the heterogeneity of diseases within this broad group, and the scarcity of well defined outcome measures. Treatment decisions are often made clinically, based on functional impairment, physiologic or radiographic progression, and exacerbating or mitigating factors such as age and comorbidity burden. We here review how to approach the patient with CTD-ILD, with a focus on long-term treatment strategies.
INITIAL APPROACH TO THE PATIENT WITH CONNECTIVE TISSUE DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASE
The rheumatologist must maintain a high level of suspicion for ILD in patients with known CTD, as subclinical disease is common and even clinically apparent symptoms are often nonspecific, insidious, and easy to overlook or attribute to alternative causes. For instance, fatigue and dyspnea on exertion might easily be attributed to deconditioning, anemia, or nonrheumatologic cardiac or pulmonary comorbidities. Dyspnea may be masked by inactivity because of disease-associated pain or weakness. Cough may be attributed to medication side-effects, smoking, or recurrent infections in an immunosuppressed patient. More overt manifestations, such as digital clubbing, hypoxemia, and pulmonary hypertension occur late in the disease course if at all, and are not useful for early disease screening.
We believe any patient with known or suspected CTD and complaints of dyspnea, cough with or without sputum, and/or rales on chest examination lasting more than a month should undergo workup, including HRCT and PFTs. In patients with known or suspected CTD and similar complaints lasting less than a month, chest radiograph should be considered, acknowledging that it is neither sensitive nor specific for diagnosing early ILD. There are not sufficient data to support HRCT/ PFT in these patients.
PULMONARY FUNCTION TESTING
ILD is characterized by PFT showing restrictive lung physiology and impaired diffusing capacity for carbon monoxide (DLCO), the latter frequently predating other testing abnormalities [6] . Restrictive physiology is defined as decreased total lung capacity (TLC) compared with matched controls, typically with a flow volume loop which is normal in shape but decreased in magnitude on both X and Y axes relative to controls (Fig. 2) . TLC is difficult to measure as it requires body plethysmography, and forced vital capacity (FVC), obtained through routine spirometry, is often used as a surrogate measure. Reduction in FVC also determines the severity of restrictive physiology; FVC less than 80% of control is abnormal, and FVC less than 50% of control severely abnormal. A patient with purely restrictive physiology will also demonstrate a normal ratio of forced expiratory volume in one second (FEV1) to FVC, representing the maximum proportion of vital capacity a patient can exhale in the first second of expiration. PFT should not be used in isolation to diagnose ILD as they lack specificity [15 & ].
Other clinical conditions coexisting with restrictive physiology can complicate PFT interpretation. For example, superimposed obstructive lung physiology, defined as FEV1/FVC ratio less than 0.7, causes pseudo normalization of lung volumes but severe reduction of DLCO. A disproportionate
HIGH-RESOLUTION COMPUTED TOMOGRAPHY
HRCT has become standard of care for initial evaluation of patients with suspected ILD, both to determine disease subtype (Table 2 ) and to assess disease severity. A confident radiologic diagnosis of UIP has a 90% correlation with surgical lung biopsy in the IIP population [16] , though the correlation between NSIP pattern and biopsy findings is less robust. HRCT scoring systems used to assess the severity of ILD in specific CTD will be discussed below. Prevalence estimates unclear because of lack of screening a defined by moderate-to-severe restriction on PFT or moderate-to-severe lung involvement on HRCT. ILD, interstitial lung disease; UIP, usual interstitial pneumonia; NSIP, nonspecific interstitial pneumonia; SSc, systemic sclerosis; RA, rheumatoid arthritis; CTD, connective tissue disease; HRCT, high-resolution computed tomography; LIP, lymphocytic interstitial pneumonia.
OTHER TESTING
Surgical lung biopsy is the gold standard for confirming ILD subtype. It is performed less frequently in CTD-ILD than in IIP patients, given their favorable prognosis and the frequent presence of other CTD manifestations justifying immunosuppression. A 6-min hallwalk is useful for determining functional capacity and degree of oxygen desaturation. However, it is confounded by nonpulmonary factors, such as joint pain, weakness, and anemia. It is a useful adjuvant to tracking overall functional status and hypoxemia over time, but cannot replace HRCT or PFT for ILD diagnosis or determination of severity.
TREATMENT OF CONNECTIVE TISSUE DISEASES ASSOCIATED INTERSTITIAL LUNG DISEASE
Corticosteroids have commonly been used as an initial treatment option for CTD-ILD. Although high-dose corticosteroid therapy can play a role in the treatment of some forms of CTD-ILD such as organizing pneumonia, there is little evidence to justify their use in more typical forms of CTD-ILD. The exception to this is acute, fulminant IIM-associated ILD, in which high-dose corticosteroid treatment has shown benefit. Steroids are not frequently used in SSc-ILD because of lack of proven efficacy and association with renal crisis in patients with early disease, and when used are generally limited to doses of 10 mg daily or less [17 && ]. We will focus on data for steroid-sparing treatments. No data clearly suggest that routine HRCT monitoring is useful in this population, and HRCT ] and the lack of clinical trials demonstrating improved outcomes in patients with known disease, means that RA-ILD is traditionally viewed as unresponsive to immunosuppressive treatment. In addition, existing studies do not differentiate RA-ILD patients with UIP from those with non-UIP (NSIP, organizing pneumonia, etc). This creates difficulty in determining whether those with non-UIP disease would respond more favorably to treatment.
SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
Data on the effect of early aggressive articular RA treatment on the incidence and progression of RA-ILD are conflicting. Early treatment with disease-modifying antirheumatic drugs (DMARDs) and prompt escalation to biologics as needed are thought to reduce the overall incidence of extraarticular RA manifestations. However, concern that commonly used RA treatments, both conventional DMARDs and newer biologics, may induce or exacerbate ILD, and that immunosuppressionrelated pulmonary infections may hasten pulmonary decline, may make clinicians hesitate to escalate treatment in patients with known RA-ILD. There are no data at present to recommend antifibrotic agents such as pirfenidone and nintedanib for the treatment of RA-ILD (or other CTD-ILD), though upcoming studies will address this.
There are no universally accepted guidelines regarding RA-ILD screening or treatment initiation.
A thorough history and physical examination combined with chest radiograph at RA diagnosis are a reasonable screen in patients with no pulmonary symptoms, although it may not detect early ILD because of its lack of sensitivity and the typically later onset of RA-ILD [33 && ]. Newly diagnosed RA patients with preexisting pulmonary conditions or symptoms should undergo workup, which may include HRCT and PFT, prior to initiating DMARD or biologic therapy. Current multinational recommendations advocate chest radiograph within 1 year of methotrexate initiation as well [34] . Patients with significant restrictive lung disease or HRCT abnormalities should be managed concomitantly with pulmonology. RA patients developing new pulmonary symptoms while on RA treatment should undergo PFT and chest imaging, while simultaneously excluding infection. If ILD or other abnormalities are present, pulmonology referral is reasonable, and the potential offending immunosuppressive agent(s) should be held while workup is ongoing.
The current treatment options for RA-ILD, and the data supporting them, are summarized in Supplemental Table 2 , http://links.lww.com/COR/ A33. A large number of drugs used to treat RA have been found to have direct interstitial pulmonary toxicity, or to possibly exacerbate preexisting ILD. A summary of these complications can also be found in Supplemental Table 2 , http://links.lww.com/ COR/A33. Noninterstitial pulmonary complications of these medications are not addressed here.
There are not sufficient data at present to recommend specific RA-ILD treatment, or to advise against any commonly used joint-targeted treatment, in any RA-ILD patient. For RA-UIP, referral to lung transplant center should be initiated [35] ]. Although data suggesting significant clinical benefit in RA-ILD are lacking, these agents have limited or no reports of lung toxicity, and small cohort studies and case series suggest they may stabilize lung volumes.
Extrapolating from the SSc-ILD literature, spirometry and DLCO evaluation every 3-6 months during treatment, with HRCT for unexplained clinical or spirometric worsening, are reasonable.
IDIOPATHIC INFLAMMATORY MYOSITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
IIM-ILD is common and associated with a substantially poorer prognosis than IIM overall [39 & ]. It occurs most frequently in patients with the antisynthetase syndrome, also characterized by arthritis, mechanic's hands, Raynaud's phenomenon, fever, and the presence of antiaminoacyl-tRNA synthetase antibodies such as the common anti-Jo-1 (antihistidyl-tRNA synthetase) and the rarer anti-PL-7 (antithreonyl-), anti-PL-12 (antialanyl-), anti-KS (antiasparaginyl-), and anti-OJ (antiisoleucyl-) antibodies. ILD prevalence in these patients ranges from 67 to 100%, and can precede muscle symptoms or occur without clinical myositis in 10-20% of patients [40] . Other myositis-associated antibodies, such as anti-melanoma-differentiation-associated gene 5 (MDA-5), anti-PM-SCL, and anti-Ro-52 are also associated with a higher risk of ILD as well as typical clinical phenotypes. The association between clinically amyopathic dermatomyositis, anti-MDA-5 positivity, and acute and/or rapidly progressive ILD, which all portend high mortality and poor response to immunosuppression [41, 42] is one of the most prognostically significant, especially in patients of East Asian descent. IIM-ILD ranges in severity from mild subclinical disease which does not progress, to a rapidly progressive acute interstitial pneumonitis with high short-term mortality. It is often present at diagnosis, but clinical course is variable [40, 41] and cannot be predicted from baseline evaluation. The most common patterns on HRCT are NSIP and OP, followed by UIP; diffuse alveolar damage is often present histologically in patients with acute, rapidly progressive disease [41] . Most IIM-ILD responds well to immunosuppression, though acute fulminant pneumonitis is characteristically unresponsive regardless of HRCT pattern [39 & ,43] . As in other CTD, IIM-UIP is less responsive than other forms of IIM-ILD, though still more responsive than is RA-UIP or IIP [44] . There are no conclusive correlations between specific disease phenotypes/antibodies and HRCT pattern, disease severity or treatment responsiveness. Antisynthetase antibodies have been associated with greater treatment responsiveness and risk of ILD recurrence [45] , with PL-7 and PL-12 often denoting more severe ILD [42, 46] . The association among clinically amyopathic dermatomyositis, anti-MDA-5 positivity, and acute, severe ILD is described above.
There are no generally accepted guidelines for ILD screening in IIM patients. It is important to remember that other disease-related factors (respiratory muscle weakness, aspiration and related infections, cardiac disease, iatrogenic lung injury, spontaneous pneumomediastinum, lung cancer, etc.) can cause abnormal lung physiology and HRCT findings, and might mimic ILD. Paraneoplastic lung disease must also remain a consideration given the association between IIM and occult malignancy. Studies to evaluate for these conditions may thus be helpful in distinguishing them from ILD. At baseline, all IIM patients with antisynthetase syndrome or MDA-5 antibody positivity should have screening PFT and HRCT. For others, careful history is appropriate, with evaluation both for ILD and other causes of pulmonary disease (as above) if new pulmonary symptoms develop during treatment. Patients with known IIM-ILD should start treatment once the diagnosis is confirmed, as earlier disease is generally more responsive to therapy [47, 48] . Follow-up PFT every 3-4 months if disease progresses, then every 6 months once stable, is reasonable.
Current treatment options for IIM-ILD, and the data supporting them, are summarized in Supplemental Table 3 , http://links.lww.com/COR/A33. Treatment of IIM-ILD is generally recommended, as above. However, asymptomatic IIM-ILD patients on evidence-based background immunosuppression for IIM, such as methotrexate, azathioprine, the combination of the two, IVIG or rituxan, can reasonably be monitored without specific ILD-targeted treatment, as these are frequently effective in controlling disease progression.
There are no controlled trials to support any steroid-sparing IIM-ILD treatment. Case series and small cohort studies support the use of azathioprine [49] Matteson E. Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia. Open J Rheumatol Autoimmune Dis 2012; 2:53-58. Pilot study suggesting efficacy of rituximab for stabilizing lung function in patients with rheumatoid-arthritis-associated ILD. Though rituximab is a well established treatment for articular disease in RA, this is one of the few studies supporting the use of rituximab for treatment of RA-ILD specifically. 
